Document Type
Article
Publication Date
1-2013
Abstract
Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants. The recent approval of new oral anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous thromboembolism, especially pulmonary embolism due to their improved pharmacokinetic and pharmacodynamic profiles, predictable anticoagulant response, and lack of required efficacy monitoring. This paper addresses the available literature, on-going clinical trials, highlights critical points, and discusses potential advantages and disadvantages of the new oral anticoagulants in patients with pulmonary embolism.
DOI
http://dx.doi.org/10.1155/2013/973710
Publication Information
Rudd, Kelly M. and Phillips, Elizabeth (2013). "New Oral Anticoagulants in the Treatment of Pulmonary Embolism: Efficacy, Bleeding Risk, and Monitoring." Thrombosis 2013, Article ID 973710-.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Comments
This article was originally published in: Thrombosis Volume 2013, Article ID 973710, 11 pages. http://dx.doi.org/10.1155/2013/973710